Clinical Infectious Diseases

Dr. Barbara Alexander Joins HealthTrackRx Advisory Board

Retrieved on: 
Tuesday, February 1, 2022
CEO, Infectious Diseases Society of America, Patient, Laboratory, LDT, Infection, Antimicrobial stewardship, Clinical Infectious Diseases, Duke University School of Medicine, MD, PCR, COVID, IDSA, COVID-19, Pathology, Research, MHS, Clinical, NIH, FDA, Internal medicine, LinkedIn, Solution, Associate, Pharmaceutical industry, Medicine

DENTON, Texas, Feb. 1, 2022 /PRNewswire/ -- HealthTrackRx, the nation's leading polymerase chain reaction (PCR) testing lab, today announced Barbara Alexander, MD, MHS, who recently served as President of the Infectious Diseases Society of America (IDSA), has joined its advisory board.

Key Points: 
  • DENTON, Texas, Feb. 1, 2022 /PRNewswire/ -- HealthTrackRx, the nation's leading polymerase chain reaction (PCR) testing lab, today announced Barbara Alexander, MD, MHS, who recently served as President of the Infectious Diseases Society of America (IDSA), has joined its advisory board.
  • "Dr. Alexander's expertise in infectious disease and diagnostics will offer HealthTrackRx invaluable insight," said Martin Price, Executive Chairman and CEO of HealthTrackRx.
  • Dr. Alexander is board certified in medical technology, internal medicine, medical microbiology and infectious diseases.
  • "HealthTrackRx is transforming the rapid delivery of PCR diagnostics for infectious diseases at a critical time for the world," said Dr. Alexander.

Study By Providence Researchers On Remdesivir Reinforces Need To Define Optimal Treatment Of Covid-19

Retrieved on: 
Thursday, August 19, 2021
Catholic (term), Antimicrobial stewardship, Severe acute respiratory syndrome coronavirus 2, IDSA, Physician, Research, World Health Organization, Person, Health, RDV, Hydroxychloroquine, Foundation for the National Institutes of Health, World, EUA, Hospital, Multimedia, Mortality, WHO, Patient, Clinical Infectious Diseases, Caregiver, Organization, Infection, FDA, National Institute, COVID-19, MD, Pharmaceutical industry

The research published in the Clinical Infectious Diseases journal, suggestedRemdesivir reduces mortality by 40% in COVID patients who receive treatment while on low flow oxygen.

Key Points: 
  • The research published in the Clinical Infectious Diseases journal, suggestedRemdesivir reduces mortality by 40% in COVID patients who receive treatment while on low flow oxygen.
  • Remdesivir reduces mortality by 40% in COVID patients who receive treatment while on low flow oxygen.
  • "These findings are significant because they highlight the urgent need to define optimal treatment of COVID-19.
  • It shows that Remdesivir was associated with lower mortality compared to best supportive care for certain patients.

Bio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous testing for SARS-CoV-2

Retrieved on: 
Wednesday, August 4, 2021
Sarbecovirus, Zoonoses, Respiratory diseases, Viruses, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, COVID-19

RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.

Key Points: 
  • RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.
  • The SARS-CoV-2 ASR will provide researchers and pathologists with a powerful technology for the detection of SARS-CoV-2 in fixed tissues.
  • During the pandemic, RNAscope probes have been an essential tool in elucidating the pathology of this devastating virus in over one hundred COVID-19 publications to date."
  • Bhatnagar J, Gary J, Reagan-Steiner S, Estetter LB, Tong S, et al.